Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study.

Détails

ID Serval
serval:BIB_973BDB6140B4
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study.
Périodique
Journal of Nuclear Medicine
Auteur(s)
Bischof-Delaloye A., Delaloye B., Buchegger F., Gilgien W., Studer A., Curchod S., Givel J.C., Mosimann F., Pettavel J., Mach J.P.
ISSN
0161-5505 (Print)
ISSN-L
0161-5505
Statut éditorial
Publié
Date de publication
1989
Peer-reviewed
Oui
Volume
30
Numéro
10
Pages
1646-1656
Langue
anglais
Résumé
Fifty-seven patients with suspected CEA-producing tumors were studied prospectively by radioimmunoscintigraphy (RIS) using a 123I-labeled anti-CEA monoclonal antibody (MAb) (essentially the F(ab')2 or Fab fragments) and emission computed tomography (ECT). Results of RIS were compared to those of a comprehensive diagnostic study. Final diagnosis was based on surgery, biopsy and autopsy (n = 39) or follow-up findings (n = 18). Three groups of patients were defined: Group A with suspected primary tumors (n = 11), Group B with probable (n = 19) and Group C with questionable (n = 27) tumor relapse. Eighty-eight per cent, 93% and 71% of the anatomic regions studied were correctly identified as being involved, and 97%, 97%, and 87% as being free from tumor in Groups A, B, and C, respectively. In the 27 patients from Group C with no definite diagnosis of relapse, and in whom diagnosis was most difficult, 38 tumor sites were involved. Of these, 21 were detected by both prospective RIS and repeated comprehensive study, six by RIS only and seven by conventional methods only. Four sites remained undetected by both approaches. Ten of the 21 lesions were detected by RIS more than 1 mo earlier than by any other method. Among the seven tumor sites detected by other diagnostic modalities only, three were identified at the time of RIS and four became positive more than 6 mo later. Overall diagnosis was entirely correct in 30, partially correct in 16 and incorrect in six patients studied. RIS with ECT and 123I-labeled anti-CEA MAb allows early detection of recurrence or metastasis of colorectal cancer. It thus contributes to reduced delay between diagnosis and treatment.
Mots-clé
Abdomen/radionuclide imaging, Adenocarcinoma/pathology, Adenocarcinoma/radionuclide imaging, Adult, Aged, Antibodies, Monoclonal/diagnostic use, Carcinoembryonic Antigen/immunology, Colorectal Neoplasms/pathology, Colorectal Neoplasms/radionuclide imaging, Female, Humans, Iodine Radioisotopes/diagnostic use, Liver/radionuclide imaging, Lung Neoplasms/pathology, Lung Neoplasms/radionuclide imaging, Male, Middle Aged, Neoplasm Metastasis, Pelvis/radionuclide imaging, Prospective Studies
Pubmed
Web of science
Création de la notice
28/01/2008 8:56
Dernière modification de la notice
20/08/2019 14:59
Données d'usage